Taken together, these studies provide evidence that a specific EPHA2 inhibitor may contribute to cetuximab resistance in human CRC, as recently demonstrated in vitro and in vivo by Martini and coworkers (82). Here, EPHA2 is linked to colorectal carcinoma.